| Prev Close | 15.54 |
| Day Low/High | 14.28 / 15.39 |
| 52 Wk Low/High | 12.75 / 28.88 |
| Avg Volume | 7.40M |
Mylan NV (MYL)
14.88
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 516.18M |
| Market Cap | 7.71B |
| P/E Ratio | 518.00 |
| Div & Yield | N.A. (N.A) |
Latest News
Mylan Breaks Out on the Upside From a 9-Month Base Pattern
Let's drill down on the charts of this global healthcare company.
The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
The Week Ahead: Earnings Season Is Far From Over
Disney, Qualcomm and Square are among 75 key reports we are watching.
Jim Cramer: Here's Why the Market's So Feckless and Reactive
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
While No Magic Pill, Mylan Deal Might Just Revive Drugmaker
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
A Look at Mylan's New Post-Merger Management
What new management means for Mylan shareholders moving forward.
Mylan Will Bounce Today and Become Stronger on the Short-Term Charts
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
4 Scenarios That Will Impact the Market: Market Recon
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
3 Small Biotech Stocks to Watch in the Fourth Quarter
These are just a few of the names I expect to do well to close out 2018.
3 Small Biotechs on My Q4 Watch List
These are a few of the names I expect to do well to close out 2018.
Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
How to Play Trump's New 'War' With Iran: Market Recon
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
Subscriber Comment of the Day (Part Deux)
Subscriber Comment of the Day (Part Deux): Neil S Allergan's stock is probably seeing additional weakness from two announcements: Mylan's biosmilar Botox partnership with Revance and the Food and Drug Administration's extension of the PDUFA date for...
Are Politics and Proxy Firms Killing Your Investment Returns?
Gains are being left on the table as firms and investors let their politics or social concerns get the better of them.
Generic-Drug Stocks Are Looking Sickly
I'm seeing some weakness in generic-drug stocks -- i.e., Teva Pharmaceuticals , Mylan and Mallinckrodt -- based on a New York Times article that hospitals might move into the generic-drug business.
